Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter

Innovent Biologics has entered into an exclusive global license agreement with Roche for the development and commercialization of its novel DLL3-targeted antibody drug conjugate, IBI3009. The deal includes an upfront payment of $80 million to Innovent, with potential milestone payments reaching $1 billion, alongside tiered royalties. This partnership aims to provide new treatment options for advanced small cell lung cancer.

For further insights into HK:1801 stock, check out TipRanks' Stock Analysis page.